B-type natriuretic peptide: powerful predictor of end-stage chronic heart failure in individuals with systolic dysfunction of the systemic right ventricle

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F16%3A00059977" target="_blank" >RIV/00023001:_____/16:00059977 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064190:_____/16:N0000076

Výsledek na webu

<a href="http://www.cmj.hr/default.aspx?id=12673&issue=yes" target="_blank" >http://www.cmj.hr/default.aspx?id=12673&issue=yes</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3325/cmj.2016.57.343" target="_blank" >10.3325/cmj.2016.57.343</a>

Jazyk výsledku

angličtina

Název v původním jazyce

B-type natriuretic peptide: powerful predictor of end-stage chronic heart failure in individuals with systolic dysfunction of the systemic right ventricle

Popis výsledku v původním jazyce

Aim: To assess whether B-type natriuretic peptide (BNP) can serve as a predictor of end-stage chronic heart failure (CHF) in patients with severe systolic dysfunction of the systemic right ventricle (SRV). Methods: We performed a retrospective analysis in 28 patients with severe systolic dysfunction of the SRV (ejection fraction 23 +- 6%) who were evaluated as heart transplant (HTx) candidates between May 2007 and October 2014. The primary endpoints of the study (end-stage CHF) were progressive CHF, urgent HTx, and ventricular assist device (VAD) implantation. Plasma BNP levels were measured using a chemiluminescent immunoassay. Results: During median follow-up of 29 months (interquartile range, 9-50), 3 patients died of progressive CHF, 5 patients required an urgent HTx, and 6 patients underwent VAD implantation. BNP was a strong predictor of end-stage CHF (hazard ratio per 100 ng/L: 1.079, 95% confidence interval, 1.042-1.117, P<0.001). The following variables with corresponding areas under the curve (AUC) were identified as the most significant predictors of end-stage CHF: BNP (AUC 1.00), New York Heart Association functional class class III or IV (AUC 0.98), decompensated CHF in the last year (AUC 0.96), and systolic dysfunction of the subpulmonal ventricle (AUC 0.96). Conclusion: BNP is a powerful predictor of end-stage CHF in individuals with systolic dysfunction of the SRV.

Název v anglickém jazyce

B-type natriuretic peptide: powerful predictor of end-stage chronic heart failure in individuals with systolic dysfunction of the systemic right ventricle

Popis výsledku anglicky

Aim: To assess whether B-type natriuretic peptide (BNP) can serve as a predictor of end-stage chronic heart failure (CHF) in patients with severe systolic dysfunction of the systemic right ventricle (SRV). Methods: We performed a retrospective analysis in 28 patients with severe systolic dysfunction of the SRV (ejection fraction 23 +- 6%) who were evaluated as heart transplant (HTx) candidates between May 2007 and October 2014. The primary endpoints of the study (end-stage CHF) were progressive CHF, urgent HTx, and ventricular assist device (VAD) implantation. Plasma BNP levels were measured using a chemiluminescent immunoassay. Results: During median follow-up of 29 months (interquartile range, 9-50), 3 patients died of progressive CHF, 5 patients required an urgent HTx, and 6 patients underwent VAD implantation. BNP was a strong predictor of end-stage CHF (hazard ratio per 100 ng/L: 1.079, 95% confidence interval, 1.042-1.117, P<0.001). The following variables with corresponding areas under the curve (AUC) were identified as the most significant predictors of end-stage CHF: BNP (AUC 1.00), New York Heart Association functional class class III or IV (AUC 0.98), decompensated CHF in the last year (AUC 0.96), and systolic dysfunction of the subpulmonal ventricle (AUC 0.96). Conclusion: BNP is a powerful predictor of end-stage CHF in individuals with systolic dysfunction of the SRV.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

<a href="/cs/project/NV15-27682A" target="_blank" >NV15-27682A: Využití metod sekvenování nové generace pro časnou diagnostiku a individualizovanou léčbu dilatační kardiomyopatie a příbuzných forem kardiomyopatií</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Croatian medical journal

ISSN

0353-9504

e-ISSN

—

Svazek periodika

57

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

HR - Chorvatská republika

Počet stran výsledku

8

Strana od-do

343-350

Kód UT WoS článku

000384783200005

EID výsledku v databázi Scopus

—